crisaborole

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Derm: burning, stinging

Misc: hypersensitivity reactions

Interactions ⬆ ⬇

Drug-drug:

Availability ⬆ ⬇

Route/Dosage ⬆ ⬇

(Adults and Children ≥3 mo): Apply a thin layer to affected areas twice daily. Once clinical effect achieved, may ↓ frequency of application to once daily.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Inhibits phosphodiesterase 4 (PDE-4) resulting in ↑ intracellular cyclic adenosine monophosphate levels.

Therapeutic effects:

Classifications ⬆ ⬇

Therapeutic Classification: anti-inflammatories

Pharmacologic Classification: phosphodiesterase type 4 inhibitors

Pharmacokinetics ⬆ ⬇

Absorption: Minimal systemic absorption through intact skin.

Distribution: Local distribution after topical administration.

Protein Binding: 97%.

Metabolism/Excretion: Metabolized through liver into inactive metabolites; metabolites excreted in urine.

Half-Life: Unknown.

Time/Action Profile ⬆ ⬇

(improvement in symptoms)

ROUTE	ONSET	PEAK	DURATION
Topical	8 days	unknown	unknown

Patient/Family Teaching ⬆ ⬇

Instruct patient or parent to apply as directed. For topical use only.
Advise patient or parent to discontinue therapy and notify health care professional if signs and symptoms of hypersensitivity (pruritus, swelling, erythema) at application site or a distant site occur.
Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
Rep: Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding.